MeSH term
Frequency | Condition_Probility | Arthritis, Rheumatoid/*genetics | 21 | 28.0 |
Computer Simulation | 3 | 0.0 |
Family | 4 | 1.0 |
Gene Frequency/genetics | 5 | 1.0 |
Genotype | 156 | 1.0 |
Humans | 703 | 0.0 |
Linkage (Genetics)/*genetics | 3 | 1.0 |
Microsatellite Repeats/genetics | 6 | 1.0 |
Research Support, Non-U.S. Gov't | 436 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 112 | 0.0 |
Antirheumatic Agents/therapeutic use | 7 | 21.0 |
Arthritis, Rheumatoid/*drug therapy/*genetics | 2 | 100.0 |
Female | 361 | 0.0 |
Genetic Predisposition to Disease | 98 | 4.0 |
HLA-DR Antigens/*genetics | 279 | 52.0 |
Immunoglobulin G/therapeutic use | 2 | 5.0 |
Lymphotoxin/*genetics | 4 | 5.0 |
Male | 350 | 0.0 |
Methotrexate/therapeutic use | 2 | 3.0 |
Middle Aged | 238 | 0.0 |
Polymorphism, Genetic | 78 | 1.0 |
Severity of Illness Index | 24 | 1.0 |
Treatment Outcome | 22 | 0.0 |
Tumor Necrosis Factor-alpha/*genetics | 31 | 8.0 |
Diabetes Mellitus, Type 1/epidemiology/*genetics | 2 | 9.0 |
Genetic Markers | 22 | 0.0 |
HLA-DQ Antigens/genetics | 63 | 24.0 |
HLA-DR Antigens/genetics | 91 | 23.0 |
Histocompatibility Testing/methods | 8 | 18.0 |
Risk Assessment | 3 | 0.0 |
Aged | 158 | 0.0 |
Arthritis, Rheumatoid/*epidemiology/*genetics | 2 | 66.0 |
Comparative Study | 78 | 0.0 |
Epitopes/*genetics | 7 | 23.0 |
*Genetic Heterogeneity | 2 | 1.0 |
Risk Factors | 54 | 0.0 |
Sex Distribution | 8 | 3.0 |
Adult | 283 | 0.0 |
Child | 98 | 0.0 |
Family Health | 9 | 0.0 |
Japan | 48 | 3.0 |
Case-Control Studies | 61 | 1.0 |
Chromosome Mapping | 13 | 0.0 |
European Continental Ancestry Group | 12 | 1.0 |
*Genes, MHC Class II | 62 | 20.0 |
HLA-DR3 Antigen/*genetics | 6 | 20.0 |
Histocompatibility Testing | 76 | 9.0 |
Lod Score | 4 | 0.0 |
Alleles | 275 | 3.0 |
Hepatitis B Surface Antigens/immunology | 2 | 8.0 |
Lymphocyte Activation | 8 | 0.0 |
*Polymorphism, Genetic | 71 | 1.0 |
Vaccination | 2 | 1.0 |
ATP-Binding Cassette Transporters/*genetics | 5 | 2.0 |
Adolescent | 135 | 0.0 |
Colombia | 3 | 6.0 |
Cross-Sectional Studies | 9 | 0.0 |
HLA-DQ Antigens/*genetics | 102 | 26.0 |
Linkage Disequilibrium | 42 | 5.0 |
Major Histocompatibility Complex/genetics | 3 | 5.0 |
Epitopes/genetics | 12 | 13.0 |
*Genetic Predisposition to Disease | 48 | 4.0 |
Aged, 80 and over | 51 | 0.0 |
*Haplotypes | 15 | 6.0 |
Histocompatibility Antigens Class II/*genetics | 46 | 24.0 |
Gene Frequency | 156 | 3.0 |
Phenotype | 41 | 0.0 |
Promoter Regions (Genetics) | 4 | 0.0 |
Cohort Studies | 27 | 1.0 |
Haplotypes | 93 | 4.0 |
Adenine | 2 | 3.0 |
Antigens, Differentiation/*genetics | 5 | 3.0 |
Child, Preschool | 56 | 0.0 |
Diabetes Mellitus, Type 1/*genetics | 16 | 7.0 |
France | 5 | 1.0 |
*Polymorphism, Single Nucleotide | 4 | 0.0 |
English Abstract | 40 | 0.0 |
HLA-B Antigens/genetics | 11 | 5.0 |
Histocompatibility Antigens Class I/*genetics | 17 | 5.0 |
Tumor Necrosis Factor-alpha/genetics | 15 | 7.0 |
Disease Susceptibility | 27 | 3.0 |
Retrospective Studies | 26 | 0.0 |
Brazil | 11 | 4.0 |
Gene Frequency/*genetics | 2 | 1.0 |
Polymerase Chain Reaction | 135 | 1.0 |
Variation (Genetics) | 6 | 0.0 |
Chi-Square Distribution | 12 | 1.0 |
Genetic Screening | 5 | 0.0 |
Iran | 2 | 5.0 |
DNA/genetics | 14 | 0.0 |
DNA Primers/chemistry | 4 | 0.0 |
Odds Ratio | 20 | 1.0 |
Taiwan | 5 | 2.0 |
Autoimmune Diseases/*genetics | 6 | 14.0 |
Chronic Disease | 5 | 0.0 |
Antibody Formation | 4 | 0.0 |
B-Lymphocytes/immunology | 2 | 0.0 |
CD4-Positive T-Lymphocytes/*immunology | 5 | 0.0 |
Epitopes | 15 | 1.0 |
Genes, MHC Class I | 2 | 1.0 |
Genes, MHC Class II | 18 | 7.0 |
Pedigree | 13 | 0.0 |
Arthritis, Rheumatoid/*genetics/immunology | 14 | 29.0 |
HLA-DR Antigens/*genetics/immunology | 26 | 50.0 |
Autoantibodies/*immunology | 4 | 1.0 |
Autoantigens/*immunology | 5 | 3.0 |
B-Lymphocytes/*immunology | 2 | 0.0 |
Epitopes/immunology | 5 | 0.0 |
Europe | 7 | 2.0 |
HLA-DQ Antigens | 2 | 6.0 |
Prevalence | 8 | 0.0 |
*RNA, Small Cytoplasmic | 3 | 11.0 |
Ribonucleoproteins/*immunology | 3 | 23.0 |
Follow-Up Studies | 22 | 0.0 |
Predictive Value of Tests | 12 | 0.0 |
Amino Acid Substitution | 4 | 0.0 |
Survival Analysis | 10 | 0.0 |
Asian Continental Ancestry Group | 8 | 2.0 |
Biopsy | 3 | 0.0 |
Expressed Sequence Tags | 2 | 0.0 |
Genetic Predisposition to Disease/*genetics | 17 | 4.0 |
Microsatellite Repeats | 19 | 1.0 |
DNA/analysis | 28 | 3.0 |
HLA-DQ Antigens/blood/*genetics | 2 | 66.0 |
HLA-DR Antigens/blood/genetics | 2 | 28.0 |
Heterozygote Detection | 3 | 0.0 |
Lupus Erythematosus, Systemic/*genetics/*immunology | 3 | 20.0 |
Polymorphism, Genetic/*genetics | 16 | 1.0 |
*Promoter Regions (Genetics) | 6 | 0.0 |
Polymorphism, Single Nucleotide | 3 | 0.0 |
Promoter Regions (Genetics)/*genetics | 5 | 0.0 |
*Chromosome Mapping | 3 | 0.0 |
Great Britain | 6 | 2.0 |
*Linkage (Genetics) | 5 | 0.0 |
*Nuclear Family | 2 | 11.0 |
Diabetes Mellitus, Type 1/genetics/*immunology | 3 | 6.0 |
Immunity, Natural/*genetics | 2 | 12.0 |
Models, Genetic | 3 | 0.0 |
Diabetes Mellitus, Type 1/*genetics/immunology | 6 | 10.0 |
Glutamate Decarboxylase/immunology | 4 | 13.0 |
HLA Antigens/genetics | 7 | 2.0 |
*Immunoconjugates | 3 | 0.0 |
Infant | 25 | 0.0 |
Polymorphism, Restriction Fragment Length | 41 | 1.0 |
Chile | 2 | 3.0 |
Prognosis | 28 | 0.0 |
Prospective Studies | 13 | 0.0 |
Arthritis, Rheumatoid/drug therapy/*genetics | 2 | 40.0 |
Ethnic Groups/genetics | 9 | 4.0 |
Hispanic Americans/*genetics | 2 | 10.0 |
Indians, South American/*genetics | 4 | 6.0 |
Reference Values | 16 | 0.0 |
Graft Survival | 7 | 1.0 |
*Hematopoietic Stem Cell Transplantation | 3 | 0.0 |
Transplantation Chimera | 3 | 8.0 |
Transplantation, Homologous | 13 | 1.0 |
Age of Onset | 16 | 1.0 |
Antirheumatic Agents/*therapeutic use | 3 | 5.0 |
Arthrography | 8 | 40.0 |
Drug Therapy, Combination | 2 | 0.0 |
Rheumatoid Factor/analysis | 3 | 4.0 |
Spain | 11 | 3.0 |
Asian Continental Ancestry Group/genetics | 10 | 2.0 |
*Gene Frequency | 22 | 4.0 |
Polymerase Chain Reaction/methods | 20 | 1.0 |
DNA Mutational Analysis | 2 | 0.0 |
Disease Progression | 18 | 0.0 |
Genetic Predisposition to Disease/genetics | 13 | 3.0 |
Longitudinal Studies | 5 | 0.0 |
Time Factors | 18 | 0.0 |
HLA-DR Antigens/*analysis/*genetics | 2 | 100.0 |
Morocco/ethnology | 2 | 12.0 |
Sequence Analysis, DNA | 4 | 0.0 |
China | 13 | 2.0 |
DNA Primers | 12 | 0.0 |
HLA-DR4 Antigen/*genetics | 11 | 36.0 |
Hepatitis, Autoimmune/*genetics | 2 | 50.0 |
*Corneal Transplantation | 2 | 9.0 |
Graft Rejection | 2 | 1.0 |
HLA-DR Antigens/*immunology | 15 | 11.0 |
*Alleles | 84 | 6.0 |
*Genetics, Population | 3 | 0.0 |
HLA Antigens/*genetics | 17 | 2.0 |
*Linkage Disequilibrium | 7 | 4.0 |
Tuberculosis, Pulmonary/*genetics/immunology | 3 | 42.0 |
China/epidemiology | 2 | 1.0 |
Narcolepsy/*genetics | 5 | 62.0 |
China/ethnology | 12 | 6.0 |
Phylogeny | 8 | 0.0 |
Spain/epidemiology | 7 | 4.0 |
European Continental Ancestry Group/*genetics | 12 | 3.0 |
Germany | 3 | 0.0 |
Molecular Sequence Data | 90 | 0.0 |
Point Mutation | 3 | 0.0 |
Fluorescent Dyes | 2 | 0.0 |
Polymerase Chain Reaction/*methods | 18 | 3.0 |
HLA-DP Antigens/genetics | 10 | 20.0 |
Asian Continental Ancestry Group/*genetics | 17 | 4.0 |
HLA-DR Antigens/*blood | 2 | 10.0 |
HLA-DR Antigens/blood/*genetics | 6 | 85.0 |
Antilymphocyte Serum/*therapeutic use | 2 | 6.0 |
HLA-DR Antigens/analysis | 11 | 1.0 |
Homozygote | 13 | 0.0 |
Nerve Tissue Proteins/*genetics | 2 | 0.0 |
Double-Blind Method | 2 | 0.0 |
Patient Selection | 5 | 2.0 |
Sialoglycoproteins/*genetics | 2 | 3.0 |
Treatment Failure | 2 | 0.0 |
Africa/ethnology | 2 | 4.0 |
African Continental Ancestry Group/genetics | 10 | 3.0 |
Autoantibodies/analysis | 4 | 2.0 |
Foot/radiography | 2 | 50.0 |
Hand/radiography | 2 | 15.0 |
Indians, South American/genetics | 2 | 16.0 |
Joints/pathology | 4 | 17.0 |
Rheumatoid Factor/blood | 6 | 15.0 |
Genetic Heterogeneity | 2 | 0.0 |
European Continental Ancestry Group/genetics | 18 | 2.0 |
Lupus Erythematosus, Systemic/*genetics | 8 | 13.0 |
Microsatellite Repeats/*genetics | 7 | 2.0 |
Multivariate Analysis | 9 | 0.0 |
Polymorphism, Genetic/genetics | 8 | 1.0 |
*Histocompatibility | 4 | 7.0 |
Life Tables | 2 | 1.0 |
Proportional Hazards Models | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 18 | 0.0 |
*Tissue Donors | 13 | 9.0 |
Tissue and Organ Procurement | 4 | 18.0 |
Transplantation Conditioning | 2 | 3.0 |
United States/epidemiology | 3 | 0.0 |
HLA-A Antigens/genetics | 5 | 3.0 |
Proteins/*genetics | 2 | 0.0 |
Thailand | 7 | 4.0 |
*Variation (Genetics) | 3 | 0.0 |
Arthritis, Juvenile Rheumatoid/*genetics | 4 | 23.0 |
Confidence Intervals | 2 | 0.0 |
Finland | 2 | 0.0 |
HLA-DP Antigens/*genetics | 12 | 14.0 |
Haplotypes/*genetics | 10 | 5.0 |
Major Histocompatibility Complex/*genetics | 14 | 8.0 |
Antigens, CD/*genetics | 3 | 1.0 |
Haplotypes/genetics | 15 | 2.0 |
Nuclear Family | 5 | 2.0 |
Receptors, Tumor Necrosis Factor/*genetics | 2 | 3.0 |
Receptors, Tumor Necrosis Factor, Type II | 4 | 1.0 |
United States | 3 | 0.0 |
Autoantibodies/*analysis | 5 | 2.0 |
Insulin/immunology | 2 | 15.0 |
Logistic Models | 10 | 1.0 |
Cameroon | 2 | 9.0 |
Autoantibodies/blood | 10 | 5.0 |
Receptors, CCR5/*genetics | 2 | 1.0 |
Comorbidity | 2 | 0.0 |
Japan/epidemiology | 8 | 2.0 |
Base Sequence | 70 | 0.0 |
*Polymorphism, Restriction Fragment Length | 9 | 1.0 |
Restriction Mapping | 2 | 0.0 |
Sequence Alignment | 9 | 0.0 |
HLA-D Antigens/*genetics | 21 | 14.0 |
Arthritis, Rheumatoid/*immunology | 4 | 1.0 |
HLA-DR4 Antigen/genetics | 9 | 31.0 |
Mexico/ethnology | 3 | 11.0 |
Epitopes/genetics/immunology | 5 | 13.0 |
Rheumatoid Factor/*blood | 3 | 16.0 |
Peru | 2 | 4.0 |
Continental Population Groups | 4 | 2.0 |
Exons/genetics | 4 | 0.0 |
HLA-DR2 Antigen/*genetics | 6 | 30.0 |
Oceanic Ancestry Group/genetics | 2 | 14.0 |
Polymorphism, Genetic/*immunology | 3 | 9.0 |
Sequence Homology, Nucleic Acid | 8 | 0.0 |
Amino Acid Sequence | 38 | 0.0 |
Models, Molecular | 4 | 0.0 |
Peptides/immunology | 3 | 2.0 |
Protein Structure, Secondary | 2 | 0.0 |
*Family Health | 2 | 3.0 |
Centromere/immunology | 3 | 27.0 |
Liver Cirrhosis, Biliary/*genetics | 2 | 33.0 |
Bone Marrow Transplantation/immunology | 3 | 8.0 |
Arthritis, Rheumatoid/epidemiology/*genetics/*immunology | 4 | 80.0 |
HLA-DR Antigens/*genetics/*immunology | 4 | 57.0 |
Animals | 37 | 0.0 |
Arthritis, Rheumatoid/*genetics/immunology/physiopathology | 2 | 66.0 |
Infant, Newborn | 10 | 0.0 |
Mediterranean Region | 3 | 14.0 |
Incidence | 11 | 0.0 |
Russia/epidemiology | 2 | 8.0 |
Socioeconomic Factors | 3 | 1.0 |
Age Distribution | 4 | 1.0 |
Genetics, Population | 9 | 2.0 |
Probability | 5 | 0.0 |
Amino Acid Substitution/genetics | 2 | 0.0 |
Bone Marrow Transplantation | 3 | 1.0 |
Exons | 9 | 0.0 |
Models, Statistical | 4 | 2.0 |
Poland/epidemiology | 2 | 3.0 |
Serotyping | 3 | 1.0 |
Analysis of Variance | 3 | 0.0 |
Arthritis, Rheumatoid/*genetics/*immunology | 7 | 33.0 |
Acute Disease | 8 | 0.0 |
Bone Marrow Transplantation/*immunology | 10 | 8.0 |
HLA-A Antigens/*immunology | 3 | 3.0 |
HLA-B Antigens/*immunology | 3 | 4.0 |
Recurrence | 7 | 0.0 |
Survivors | 2 | 2.0 |
Tissue Donors | 15 | 5.0 |
Genes, MHC Class I/*genetics | 5 | 6.0 |
Genes, MHC Class II/*genetics | 13 | 19.0 |
Cyclosporine/therapeutic use | 3 | 4.0 |
Graft Survival/*immunology | 8 | 14.0 |
HLA-DR Antigens/genetics/*immunology | 13 | 39.0 |
*Histocompatibility Testing | 21 | 10.0 |
Immunosuppressive Agents/therapeutic use | 6 | 2.0 |
Kidney Transplantation/*immunology | 17 | 8.0 |
Graft Survival/immunology | 3 | 5.0 |
Muromonab-CD3/therapeutic use | 2 | 15.0 |
Steroids/therapeutic use | 2 | 5.0 |
Survival Rate | 7 | 0.0 |
Disease Susceptibility/immunology | 9 | 12.0 |
Outcome Assessment (Health Care) | 2 | 4.0 |
Polymyalgia Rheumatica/*genetics | 4 | 80.0 |
Amino Acid Sequence/genetics | 3 | 1.0 |
Aspartic Acid/*genetics | 2 | 15.0 |
Genetic Screening/methods | 2 | 1.0 |
Histocompatibility Antigens Class II/genetics | 12 | 10.0 |
Antigens, CD/genetics | 2 | 1.0 |
DNA Primers/genetics | 5 | 0.0 |
Receptors, Tumor Necrosis Factor/genetics | 2 | 4.0 |
Serologic Tests | 3 | 3.0 |
Poland | 2 | 1.0 |
African Americans | 4 | 3.0 |
Ethnic Groups/*genetics | 7 | 3.0 |
Heterozygote | 10 | 0.0 |
Histocompatibility Testing/*methods | 19 | 12.0 |
Sensitivity and Specificity | 12 | 0.0 |
Sequence Analysis, DNA/*methods | 3 | 4.0 |
T-Lymphocytes/*immunology | 3 | 0.0 |
Recombination, Genetic | 2 | 0.0 |
Disease Models, Animal | 3 | 0.0 |
Gene Transfer Techniques | 2 | 0.0 |
Histocompatibility Antigens Class II/genetics/*immunology | 4 | 13.0 |
Mice | 10 | 0.0 |
Mice, Transgenic | 5 | 0.0 |
Thyroglobulin/*immunology | 2 | 2.0 |
Thyroiditis, Autoimmune/*immunology/physiopathology | 2 | 100.0 |
Transgenes | 2 | 0.0 |
Pregnancy | 8 | 0.0 |
Histocompatibility Antigens Class II | 2 | 4.0 |
Lymphotoxin/genetics | 8 | 13.0 |
Promoter Regions (Genetics)/genetics | 5 | 0.0 |
Indians, North American/genetics | 2 | 5.0 |
*Selection (Genetics) | 2 | 3.0 |
Korea/epidemiology | 6 | 10.0 |
Autoantibodies/*blood | 5 | 1.0 |
DNA Topoisomerases, Type I/*immunology | 3 | 50.0 |
Recombinant Proteins/immunology | 3 | 0.0 |
Scleroderma, Systemic/*immunology | 3 | 11.0 |
HLA-DQ Antigens/classification/*genetics | 6 | 40.0 |
HLA-DR Antigens/classification/*genetics | 9 | 60.0 |
Mexico/epidemiology | 2 | 6.0 |
Italy | 9 | 1.0 |
Allergens/immunology | 2 | 2.0 |
Asthma/*genetics | 2 | 3.0 |
Polymorphism, Single-Stranded Conformational | 12 | 0.0 |
Skin Tests | 3 | 1.0 |
*Introns | 2 | 0.0 |
Polymorphism, Genetic/immunology | 4 | 16.0 |
Recombination, Genetic/*immunology | 2 | 50.0 |
*Aging | 2 | 1.0 |
Diet | 2 | 0.0 |
HLA-DQ Antigens/analysis | 5 | 10.0 |
Chromosomes, Human, Pair 6 | 3 | 1.0 |
Croatia | 3 | 8.0 |
*Bone Marrow Transplantation | 6 | 1.0 |
Oligonucleotide Probes | 28 | 4.0 |
*Polymorphism, Single-Stranded Conformational | 3 | 2.0 |
Ethnic Groups | 5 | 2.0 |
HLA-DR Antigens/*analysis/genetics | 5 | 20.0 |
Algorithms | 2 | 0.0 |
HLA-DQ Antigens/immunology | 5 | 12.0 |
HLA-DR Antigens/immunology | 8 | 3.0 |
In Vitro | 3 | 0.0 |
T-Lymphocytes, Cytotoxic/*immunology | 3 | 0.0 |
Antigens, Differentiation/genetics | 2 | 6.0 |
Diabetes Mellitus, Type 1/blood/*genetics/*immunology | 2 | 33.0 |
Genes, MHC Class II/genetics | 3 | 10.0 |
Cloning, Molecular | 5 | 0.0 |
Immunophenotyping | 3 | 0.0 |
*Minisatellite Repeats | 2 | 2.0 |
Chromosomes, Human, Pair 6/genetics | 3 | 2.0 |
Biological Markers | 2 | 0.0 |
Single-Blind Method | 2 | 0.0 |
Graft Rejection/immunology | 2 | 3.0 |
HLA-A Antigens/immunology | 5 | 7.0 |
HLA-B Antigens/immunology | 4 | 6.0 |
Antigen Presentation | 2 | 0.0 |
CD4-Positive T-Lymphocytes/immunology | 2 | 0.0 |
Cell Line | 12 | 0.0 |
HLA Antigens | 4 | 3.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Histocompatibility Antigens Class I/genetics | 3 | 3.0 |
Immunogenetics | 3 | 6.0 |
African Continental Ancestry Group/*genetics | 11 | 4.0 |
HLA-DR1 Antigen/*genetics | 4 | 23.0 |
Population Surveillance | 2 | 1.0 |
Sampling Studies | 4 | 2.0 |
Arthritis, Rheumatoid/genetics/*physiopathology | 2 | 100.0 |
Endothelium, Vascular/*physiopathology | 2 | 2.0 |
Vasodilation | 2 | 5.0 |
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use | 2 | 4.0 |
Enzyme-Linked Immunosorbent Assay | 5 | 0.0 |
Antigens, Dermatophagoides | 2 | 3.0 |
HLA-DP Antigens/*genetics/immunology | 3 | 42.0 |
Risk | 5 | 0.0 |
Sex Factors | 7 | 0.0 |
Celiac Disease/*genetics | 2 | 7.0 |
HLA-DR3 Antigen/genetics | 5 | 20.0 |
Arthritis, Rheumatoid/diagnosis/*genetics | 2 | 50.0 |
Genetic Markers/physiology | 2 | 40.0 |
Arthritis, Rheumatoid/genetics/*immunology | 2 | 5.0 |
Receptors, IgG/*genetics | 3 | 13.0 |
Neoplasm Staging | 2 | 0.0 |
Turkey | 2 | 1.0 |
Adrenal Cortex Hormones/therapeutic use | 2 | 2.0 |
*Arthrography | 2 | 50.0 |
*Epitopes | 3 | 2.0 |
HLA Antigens/*immunology | 5 | 1.0 |
Czech Republic | 2 | 4.0 |
Evaluation Studies | 5 | 0.0 |
*Lymphocyte Culture Test, Mixed | 3 | 5.0 |
Age Factors | 8 | 0.0 |
DNA Probes | 8 | 0.0 |
Nucleic Acid Hybridization | 9 | 0.0 |
Antigens, Bacterial/immunology | 2 | 1.0 |
Epitope Mapping | 2 | 0.0 |
Glycoproteins/*immunology | 2 | 2.0 |
India | 2 | 0.0 |
Carrier State/immunology | 2 | 13.0 |
Cells, Cultured | 3 | 0.0 |
HLA-DQ Antigens/*genetics/immunology | 10 | 38.0 |
Lupus Erythematosus, Systemic/epidemiology/*genetics | 2 | 33.0 |
Antibodies, Monoclonal/*immunology | 2 | 0.0 |
Histocompatibility | 4 | 3.0 |
*HIV-1 | 2 | 0.0 |
Multiple Sclerosis/*genetics/immunology | 4 | 23.0 |
Multiple Sclerosis/ethnology/*genetics/immunology | 2 | 66.0 |
Amino Acid Motifs | 3 | 0.0 |
Arthritis, Rheumatoid/*genetics/radiography | 2 | 100.0 |
Protein Conformation | 2 | 0.0 |
Argentina | 3 | 6.0 |
Autoantibodies/immunology | 2 | 1.0 |
HLA-DQ Antigens/genetics/immunology | 5 | 25.0 |
HLA-DR Antigens/chemistry/genetics/immunology | 2 | 100.0 |
Hepatitis, Autoimmune/*genetics/*immunology/physiopathology/therapy | 2 | 100.0 |
Linkage Disequilibrium/genetics | 5 | 3.0 |
Amino Acids/*genetics | 3 | 30.0 |
Colitis, Ulcerative/*genetics/metabolism | 2 | 100.0 |
HLA-DR Antigens/*genetics/metabolism | 3 | 33.0 |
Temporal Arteritis/*genetics | 3 | 100.0 |
Gene Frequency/immunology | 2 | 13.0 |
*Histocompatibility Antigens Class II | 2 | 3.0 |
Mexico | 5 | 5.0 |
Behcet Syndrome/*genetics | 2 | 8.0 |
Saudi Arabia | 2 | 4.0 |
Cyclophosphamide/therapeutic use | 2 | 2.0 |
Whole-Body Irradiation | 2 | 2.0 |
Pilot Projects | 2 | 0.0 |
Reproducibility of Results | 4 | 0.0 |
HLA-A Antigens/*genetics | 7 | 3.0 |
HLA-B Antigens/*genetics | 7 | 2.0 |
Electrophoresis | 3 | 1.0 |
*Heterozygote | 3 | 0.0 |
*Hematopoietic Stem Cell Transplantation/adverse effects | 2 | 5.0 |
Histocompatibility/*immunology | 2 | 13.0 |
Regression Analysis | 3 | 0.0 |
Scleroderma, Systemic/*genetics/*immunology | 2 | 33.0 |
Diabetes Mellitus, Type 1/*genetics/*immunology | 4 | 18.0 |
*Genotype | 4 | 1.0 |
Random Allocation | 3 | 0.0 |
Rheumatoid Nodule/etiology | 2 | 100.0 |
*Asian Continental Ancestry Group | 2 | 3.0 |
Korea | 3 | 1.0 |
Arthritis, Rheumatoid/epidemiology/*genetics/immunology | 2 | 50.0 |
France/epidemiology | 4 | 2.0 |
*Evolution, Molecular | 2 | 0.0 |
Multiple Sclerosis/*genetics | 6 | 7.0 |
HLA-DR Antigens/*analysis | 5 | 2.0 |
Magnetic Resonance Imaging | 4 | 0.0 |
Polymyalgia Rheumatica/*genetics/immunology | 2 | 66.0 |
Hepatitis B Vaccines/*immunology | 2 | 15.0 |
Lymphocytes/*immunology | 2 | 0.0 |
T-Lymphocytes/immunology | 2 | 0.0 |
HLA-DR Antigens/analysis/*immunology | 2 | 18.0 |
Rheumatoid Factor/biosynthesis | 2 | 40.0 |
Continental Population Groups/genetics | 3 | 3.0 |
ATP-Binding Cassette Transporters/genetics | 2 | 3.0 |
Sjogren's Syndrome/*genetics | 3 | 30.0 |
DNA/*analysis | 4 | 1.0 |
HLA-DR Antigens/analysis/genetics | 2 | 7.0 |
Gene Dosage | 3 | 0.0 |
Complement 4/*genetics | 3 | 2.0 |
Lupus Erythematosus, Systemic/*genetics/immunology | 4 | 8.0 |
HLA-DQ Antigens/genetics/*immunology | 6 | 46.0 |
Siberia | 3 | 7.0 |
*Genes, MHC Class I | 4 | 1.0 |
*HLA-DR Antigens/genetics | 3 | 50.0 |
Disease-Free Survival | 2 | 0.0 |
Graft vs Host Disease/etiology | 3 | 5.0 |
Registries | 2 | 0.0 |
*Evolution | 2 | 1.0 |
Linkage (Genetics) | 13 | 0.0 |
Data Interpretation, Statistical | 2 | 0.0 |
Slovakia | 2 | 9.0 |
*Chromosomes, Human, Pair 6 | 3 | 1.0 |
Hispanic Americans | 2 | 3.0 |
Lupus Erythematosus, Systemic/genetics/*immunology | 2 | 6.0 |
HLA Antigens/blood | 3 | 25.0 |
Histocompatibility Antigens Class II/*genetics/immunology | 8 | 40.0 |
Genetic Markers/genetics | 2 | 0.0 |
Egypt | 2 | 4.0 |
HLA-DR3 Antigen/*immunology | 2 | 50.0 |
Histocompatibility Antigens Class II/chemistry/*genetics | 2 | 50.0 |
Longevity/*genetics | 2 | 5.0 |
HLA-DR2 Antigen/genetics/immunology | 2 | 50.0 |
Italy/epidemiology | 2 | 0.0 |
Graft Rejection/genetics | 2 | 28.0 |
HLA-DR Antigens/analysis/*genetics | 5 | 38.0 |
*Graft Survival | 4 | 2.0 |
Kidney Transplantation/*immunology/physiology | 2 | 16.0 |
Arthritis, Rheumatoid/ethnology/*genetics/immunology | 2 | 50.0 |
HIV Seropositivity | 2 | 1.0 |
Heterosexuality | 2 | 10.0 |
Zambia | 2 | 14.0 |
RNA, Viral/blood | 2 | 0.0 |
Protein Binding | 5 | 0.0 |
Nucleic Acid Denaturation | 2 | 2.0 |
Prolactin/*genetics | 2 | 6.0 |
*Exons | 2 | 0.0 |
Histocompatibility Antigens Class II/*immunology | 3 | 1.0 |
Immunity, Natural/genetics | 2 | 3.0 |
Lymphocyte Culture Test, Mixed | 3 | 0.0 |
Evolution, Molecular | 2 | 0.0 |
HLA-DR2 Antigen/genetics | 2 | 11.0 |
Lupus Nephritis/genetics | 2 | 50.0 |
Taiwan/epidemiology | 2 | 1.0 |
Receptors, Antigen, T-Cell, alpha-beta/*genetics | 2 | 2.0 |
T-Lymphocytes, Helper-Inducer/*immunology | 2 | 1.0 |
Genes, MHC Class II/*immunology | 4 | 20.0 |
Corneal Transplantation/*immunology | 2 | 16.0 |
Ligands | 2 | 0.0 |
Mutation | 2 | 0.0 |
Cadaver | 11 | 4.0 |
*HLA-DR Antigens | 2 | 14.0 |
Kidney Transplantation/immunology/*physiology | 2 | 10.0 |
Waiting Lists | 2 | 9.0 |
Administration, Oral | 2 | 0.0 |
DNA | 6 | 0.0 |
*Polymerase Chain Reaction | 9 | 4.0 |
Population | 2 | 7.0 |
Genetic Predisposition to Disease/epidemiology/genetics | 3 | 14.0 |
Drug Resistance/genetics | 2 | 1.0 |
CD4 Lymphocyte Count | 3 | 0.0 |
Allergens/*immunology | 3 | 3.0 |
Autoimmune Diseases/genetics | 2 | 7.0 |
Immunosuppression/methods | 3 | 9.0 |
HLA-DR Antigens/*classification/genetics | 2 | 50.0 |
Nucleic Acid Hybridization/*methods | 2 | 4.0 |
Hypersensitivity, Immediate/*genetics | 2 | 14.0 |
Gene Amplification | 4 | 0.0 |
HLA-DR Antigens/genetics/immunology | 3 | 9.0 |
Oceanic Ancestry Group/*genetics | 2 | 8.0 |
Haplotypes/*immunology | 2 | 8.0 |
Cytokines/genetics | 2 | 1.0 |
HLA-DR4 Antigen/analysis | 2 | 11.0 |
Autoimmune Diseases/genetics/*immunology | 2 | 10.0 |
Autoimmune Diseases/*genetics/immunology | 2 | 11.0 |
Introns | 2 | 0.0 |
Diabetes Mellitus, Type 1/epidemiology/*genetics/*immunology | 3 | 33.0 |
Antigens, CD45/genetics | 2 | 28.0 |
T-Lymphocyte Subsets/immunology | 2 | 0.0 |
Cluster Analysis | 2 | 1.0 |
Interferon Type II/genetics | 2 | 2.0 |
Autoantigens/immunology | 2 | 1.0 |
Norway | 2 | 1.0 |
HLA-DP Antigens/genetics/*immunology | 3 | 27.0 |
Arthritis, Rheumatoid/*genetics/pathology | 2 | 22.0 |
Celiac Disease/epidemiology/*genetics | 2 | 100.0 |
*Sex Characteristics | 2 | 1.0 |
Russia | 3 | 3.0 |
Diseases in Twins | 2 | 4.0 |
Viral Load | 2 | 0.0 |
Immunoblotting | 2 | 0.0 |
Species Specificity | 2 | 0.0 |
Transplantation, Homologous/immunology | 2 | 4.0 |
DNA/*genetics | 4 | 1.0 |
Great Britain/epidemiology | 2 | 1.0 |
Polymorphism, Single Nucleotide/genetics | 2 | 0.0 |
*Oligonucleotide Probes | 2 | 8.0 |
Scleroderma, Systemic/genetics/*immunology | 2 | 28.0 |
Tumor Cells, Cultured | 2 | 0.0 |
HLA-DR Antigens/*analysis/genetics/immunology | 2 | 40.0 |
Histocompatibility Antigens Class II/*analysis/genetics/immunology | 2 | 40.0 |
Gene Deletion | 2 | 0.0 |
Gorilla gorilla | 2 | 5.0 |
Pan troglodytes | 2 | 1.0 |
Chemiluminescent Measurements | 2 | 1.0 |
Algeria | 2 | 11.0 |
*Histocompatibility Antigens Class II/genetics | 2 | 33.0 |
*Software | 2 | 3.0 |
DNA Probes, HLA/genetics | 2 | 66.0 |
Kidney Transplantation/immunology | 2 | 3.0 |
HLA-DR Antigens | 3 | 0.0 |
DNA Probes, HLA | 2 | 10.0 |
*Serology | 2 | 66.0 |
Stromelysin 1/blood/*genetics | 2 | 100.0 |
Graft Rejection/*genetics/immunology | 2 | 22.0 |
Graft Survival/*genetics/immunology | 2 | 50.0 |
Polynesia | 2 | 15.0 |
Blotting, Southern | 3 | 0.0 |
Geography | 2 | 3.0 |
Gene Expression Regulation | 2 | 0.0 |
Autoimmunity | 2 | 1.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Smoking/*adverse effects | 2 | 0.0 |
